Literature DB >> 34676466

Biomarkers of immunotherapy response in breast cancer beyond PD-L1.

Nuria Chic1,2,3, Fara Brasó-Maristany1,2,3, Aleix Prat4,5,6,7,8.   

Abstract

Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer types, including breast cancer. Nevertheless, optimal selection of ideal candidates to these drugs remains an unmet need. Although PD-L1 expression by immunohistochemistry seems to be the most promising biomarker to date, its predictive ability is far from ideal. Thus, the development of new predictive biomarkers is essential for a better selection of patients. Here, we discuss potential biomarkers beyond PD-L1 that could play an important role in precision cancer immunotherapy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Breast cancer; Immune checkpoint inhibitors; PD-L1

Mesh：

Substances：

Year:  2021        PMID： 34676466     DOI： 10.1007/s10549-021-06421-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  69 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 2.  PD-1/PD-L1 inhibitors.

Authors:  Joel Sunshine; Janis M Taube
Journal:  Curr Opin Pharmacol       Date:  2015-06-02       Impact factor: 5.547

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.

Authors:  P Schmid; R Salgado; Y H Park; E Muñoz-Couselo; S B Kim; J Sohn; S-A Im; T Foukakis; S Kuemmel; R Dent; L Yin; A Wang; K Tryfonidis; V Karantza; J Cortés; S Loi
Journal:  Ann Oncol       Date:  2020-02-14       Impact factor: 32.976

5.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Authors:  Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid
Journal:  Lancet       Date:  2020-12-05       Impact factor: 79.321

6.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Authors:  Elizabeth A Mittendorf; Hong Zhang; Carlos H Barrios; Shigehira Saji; Kyung Hae Jung; Roberto Hegg; Andreas Koehler; Joohyuk Sohn; Hiroji Iwata; Melinda L Telli; Cristiano Ferrario; Kevin Punie; Frédérique Penault-Llorca; Shilpen Patel; Anh Nguyen Duc; Mario Liste-Hermoso; Vidya Maiya; Luciana Molinero; Stephen Y Chui; Nadia Harbeck
Journal:  Lancet       Date:  2020-09-20       Impact factor: 79.321

7.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

8.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.

Authors:  S Loibl; M Untch; N Burchardi; J Huober; B V Sinn; J-U Blohmer; E-M Grischke; J Furlanetto; H Tesch; C Hanusch; K Engels; M Rezai; C Jackisch; W D Schmitt; G von Minckwitz; J Thomalla; S Kümmel; B Rautenberg; P A Fasching; K Weber; K Rhiem; C Denkert; A Schneeweiss
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

9.  Pembrolizumab for Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Theodoros Foukakis; Peter A Fasching; Fatima Cardoso; Michael Untch; Liyi Jia; Vassiliki Karantza; Jing Zhao; Gursel Aktan; Rebecca Dent; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 176.079
View more
  2 in total

1.  CD8+ T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis.

Authors:  Yijian Zhang; Li Li; Wenjie Zheng; Lei Zhang; Ninghua Yao
Journal:  Ann Transl Med       Date:  2022-03

2.  Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.

Authors:  Elahe Shenasa; Elisabeth Specht Stovgaard; Maj-Britt Jensen; Karama Asleh; Nazia Riaz; Dongxia Gao; Samuel Leung; Bent Ejlertsen; Anne-Vibeke Laenkholm; Torsten O Nielsen
Journal:  Cancers (Basel)       Date:  2022-08-05       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.